London Daily

Focus on the big picture.
Sunday, Oct 26, 2025

UK vaccine strategy 'paying off' as latest trials boost stockpiles

UK vaccine strategy 'paying off' as latest trials boost stockpiles

Pre-ordering of Janssen and Novavax means Britain has procured 247m successfully trialled jabs

Britain has cemented its status as one of the world’s leading buyers of effective Covid vaccines after two more pharmaceutical companies reported positive trial results – potentially growing the UK stockpile by 90m doses.

The US drugmaker Johnson & Johnson announced on Friday that its vaccine – which requires only one dose – is effective. This followed Thursday’s news that the Novavax vaccine, which will be manufactured in the UK, performed well in phase 3 trials.

The UK’s vaccines taskforce has pre-ordered 30m doses of the Janssen vaccine, produced by Johnson and Johnson via its Belgian subsidiary, and 60m Novavax doses, which will be administered as two doses per person if it gets regulatory approval. Both can be stored at fridge temperatures.

In total, the UK has procured 247m vaccine doses from companies with positive phase 3 results: roughly 3.7 jabs per person, Guardian analysis has found. Canada, Chile, Australia and New Zealand are the only countries with a higher rate per head, according to data from Duke Global Health Innovation Center including contracts signed up to 25 January.

While both the US and the EU have procured more than 1bn effective doses each, these numbers equate to lower rates of 3.4 and 2.4 per person. The UK has placed orders for a further 120m vaccines from Sanofi-GSK and Valneva, but these still await positive trial results.

Johnson & Johnson said its vaccine had 72% efficacy in preventing Covid in US trials, but a lower rate of 66% was observed globally in a large trial conducted across three continents and against multiple variants.

It gave people 85% protection against severe illness, even in South Africa, which is struggling with a problematic variant of the virus. The vaccine gave 100% protection against hospitalisation and death, as do the other vaccines now approved.

The health secretary, Matt Hancock, said the news meant the UK was in “pole position” in the race to protect its population against the virus. “Our approach of buying abroad and making here at home is paying off,” he said.

With case rates and hospitalisations still at high levels, ministers are keenly awaiting data on the impact of the vaccine rollout on the spread of the virus, which should begin to emerge in the next fortnight.

Boris Johnson has signalled he will wait until the week of 22 February, when more evidence will be available, before making firm decisions about lifting schools closure or other lockdown measures. The latest NHS figures, published on Friday, showed that 6.8 million people have now received their first dose of Covid vaccine in the UK.

Some health experts are calling on the UK government to consider sharing its vaccine supplies with other countries, including the EU, given the shared imperative of tackling the virus worldwide.


Boris Johnson, seen here at a lab in Scotland that will manufacture a Covid vaccine, will wait until 22 February before considering lifting lockdown measures.


Dr Alberto Giubilini, from the Oxford Uehiro Centre for Practical Ethics at the University of Oxford, said: “I think that the more vaccine doses we have in the UK, the stronger the reason to give some to the EU. It is not just about being generous, it is to make sure that the problem is addressed at the collective level, which is the only level at which it can be addressed if we want long term positive outcomes.”

A government source insisted it was too soon to contemplate whether the UK might have surplus doses, however – pointing out that the two newest vaccines must still await the approval of the regulator. “There is no expectation that we will have excess levels of supply, because of the time lag,” they said.

Vaccine availability remains the constraint on the speed of the immunisation programme, with some regions reporting inconsistent supplies. Hancock has also made clear he believes the public may need to be re-vaccinated in a year’s time, or perhaps sooner, as more evidence emerges about how long protection lasts.

Newsletter

Related Articles

0:00
0:00
Close
United States and China Begin Constructive Trade Negotiations Ahead of Trump–Xi Summit
U.S. Treasury Sanctions Colombia’s President Gustavo Petro over Drug-Trafficking Allegations
Miss USA Crowns Nebraska’s Audrey Eckert Amid Leadership Overhaul
‘I Am Not Done’: Kamala Harris Signals Possible 2028 White House Run
NBA Faces Integrity Crisis After Mass Arrests in Gambling Scandal
Swift Heist at the Louvre Sees Eight French Crown Jewels Stolen in Under Seven Minutes
U.S. Halts Trade Talks with Canada After Ontario Ad Using Reagan Voice Triggers Diplomatic Fallout
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
China and Russia Deploy Seductive Espionage Networks to Infiltrate U.S. Tech Sector
Apple’s ‘iPhone Air’ Collapses After One Month — Another Major Misstep for the Tech Giant
Graham Potter Begins New Chapter as Sweden Head Coach on Short-Term Deal
Ecuadorian President Daniel Noboa Alleges Poison Plot via Chocolate and Jam
Lakestar to Halt External Fundraising as Investor in Revolut and Spotify
U.S. Innovation Ranking Under Scrutiny as China Leads Output Outputs but Ranks 10th
Three Men Arrested in London on Suspicion of Spying for Russia
Porsche Reverses EV Strategy as New CEO Bets on Petrol and Hybrids
Singapore’s Prime Minister Warns of ‘Messy’ Transition to Post-American Global Order
Andreessen Horowitz Sets Sights on Ten-Billion-Dollar Fund for Tech Surge
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
×